Cognitive & neuro research peptides

About this category

Each product page notes what the reference literature actually used.

As with the rest of the catalogue, nothing here is characterised for human use. These are in-vitro and preclinical reference compounds supplied with lot-level analytical documentation.

• ·Short neuromodulatory sequences with published model context
• ·Half-life and administration notes drawn from reference literature
• ·≥99% HPLC main-peak purity targets, verified per batch
• ·Tracked EU shipping, research-use declaration included

Administration routes in the published cognitive models

Route affects how exposure data should be read, which is why each product page states what the reference literature actually used rather than assuming a single convention.

The compounds themselves are short neuromodulatory sequences, several derived from endogenous regulatory peptides, used as tools for probing BDNF expression and monoamine turnover in the published work. That tool-use framing — probing a pathway, not treating a condition — is how the category reads in the reference models, and it is the framing this catalogue keeps.

Comparing the pairs: where the documented behaviour differs

The two most-studied pairs in this category, Selank versus Semax and their related derivatives, differ in documented stability, route conventions and the endpoints their reference literature targets. The comparison pages lay out those differences field by field so a research design starts from the documented record.

Storage follows the same pattern as elsewhere in the catalogue: lyophilised powder tolerates short transit at ambient temperature, and long-term holding is refrigerated or frozen, protected from light once reconstituted.

Frequently asked questions